Ausgabe 6/2014
Inhalt (29 Artikel)
Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells
Victor Kuete, Louis P. Sandjo, Doriane E. Djeussi, Maen Zeino, Guy M. N. Kwamou, Bonaventure Ngadjui, Thomas Efferth
Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5’ RNA genome end methodology
S. Israelsson, A. Sävneby, J-O. Ekström, N. Jonsson, K. Edman, A. M. Lindberg
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities
Dawn N. Waterhouse, Brent W. Sutherland, Nancy Dos Santos, Dana Masin, Maryam Osooly, Dita Strutt, Christina Ostlund, Malathi Anantha, Natashia Harasym, Irina Manisali, Mohamed Wehbe, Marcel B. Bally, Murray S. Webb
“Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183”
Serena Marchetti, Dick Pluim, Jos H. Beijnen, Roberto Mazzanti, Olaf van Tellingen, Jan H. M. Schellens
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
Nicole Grabinski, Florian Ewald
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models
Sun-Hee Kim, Ofer Margalit, Hiroshi Katoh, Dingzhi Wang, Hong Wu, Dianren Xia, Vijaykumar R. Holla, Peiying Yang, Raymond N. DuBois
Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells
E. G. Russell, E. C. O’Sullivan, C. M. Miller, J. Stanicka, F. O. McCarthy, T. G. Cotter
A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer
Silvia Valtorta, Gabriella Nicolini, Farida Tripodi, Cristina Meregalli, Guido Cavaletti, Federica Avezza, Luca Crippa, Gloria Bertoli, Francesca Sanvito, Paola Fusi, Roberto Pagliarin, Fulvia Orsini, Rosa Maria Moresco, Paola Coccetti
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA
Dexin Kong, Takao Yamori, Kanami Yamazaki, Shingo Dan
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors
Florian Ewald, Dominik Nörz, Astrid Grottke, Bianca T. Hofmann, Björn Nashan, Manfred Jücker
AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L
Jerzy S. Pieczykolan, Konrad Kubiński, Maciej Masłyk, Sebastian D. Pawlak, Anna Pieczykolan, Piotr K. Rózga, Michał Szymanik, Marlena Gałązka, Małgorzata Teska-Kamińska, Bartłomiej Żerek, Katarzyna Bukato, Katarzyna Poleszak, Albert Jaworski, Wojciech Strożek, Robert Świder, Rafał Zieliński
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
Valeria Sero, Elisa Tavanti, Serena Vella, Claudia Maria Hattinger, Marilù Fanelli, Francesca Michelacci, Rogier Versteeg, Barbara Valsasina, Beth Gudeman, Piero Picci, Massimo Serra
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study
Gerald Falchook, Razelle Kurzrock, Launce Gouw, David Hong, Kimberly A. McGregor, Xiaofei Zhou, Hongliang Shi, Howard Fingert, Sunil Sharma
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
Rastislav Bahleda, Cristiana Sessa, Gianluca Del Conte, Luca Gianni, Giuseppe Capri, Andrea Varga, Corina Oprea, Byzance Daglish, Marie Hospitel, Jean-Charles Soria
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
Daniel W. Bowles, Neil Senzer, Diana Hausman, Scott Peterson, Alex Vo, Luke Walker, Roger B. Cohen, Antonio Jimeno
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors
D. S. Hong, H. Henary, G. S. Falchook, A. Naing, S. Fu, S. Moulder, J. J. Wheler, A. Tsimberidou, J. B. Durand, R. Khan, P. Yang, M. Johansen, R. A. Newman, R. Kurzrock
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Ajay K. Gopal, Stefano R. Tarantolo, Naresh Bellam, Damian J. Green, Melissa Griffin, Tatyana Feldman, Anthony R. Mato, Amy J. Eisenfeld, Scott C. Stromatt, Andre Goy
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
Quincy S. Chu, Randeep Sangha, Sebastien J. Hotte, Gwen Sergenson, David Schnell, Vikram K. Chand, Hal W. Hirte
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
A. Craig Lockhart, Shankar Sundaram, John Sarantopoulos, Monica M. Mita, Andrea Wang-Gillam, Jennifer L. Moseley, Stephanie L. Barber, Alex R. Lane, Claudine Wack, Laurent Kassalow, Jean-François Dedieu, Alain C. Mita
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
Nizar M. Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, Sumanta K. Pal, Stephen M. Ansell, Jeffrey R. Infante, Sven de Vos, Paul A. Hamlin, Stella K. Kim, Nancy C. Whiting, Elaina M. Gartner, Baiteng Zhao, John A. Thompson
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
Roberto Pili, Michael Carducci, Peter Brown, Herbert Hurwitz
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin
Irene Brana, Alberto Ocana, Eric X. Chen, Albiruni R. A. Razak, Christine Haines, Carol Lee, Sarah Douglas, Lisa Wang, Lillian L. Siu, Ian F. Tannock, Philippe L. Bedard
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
A. Ruzsa, M. Sen, M. Evans, L. W. Lee, K. Hideghety, S. Rottey, P. Klimak, P. Holeckova, J. Fayette, T. Csoszi, J. Erfan, U. Forssmann, T. Goddemeier, A. Bexon, C. Nutting
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
Meng Zhao, Xueliang Pan, Rachel Layman, Maryam B. Lustberg, Ewa Mrozek, Erin R. Macrae, Robert Wesolowski, Sarah Carothers, Shannon Puhalla, Charles L. Shapiro, Bhuvaneswari Ramaswamy
The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity
Didem Tastekin, Makbule Tambas, Kemal Kilic, Kayhan Erturk, Deniz Arslan
Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis
Daiana Renck, André A. Santos Jr, Pablo Machado, Guilherme O. Petersen, Tiago G. Lopes, Diógenes S. Santos, Maria M. Campos, Luiz A. Basso
Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors
Mélodie Carbonnaux, Yann Molin, Pierre-Jean Souquet, Arnaud Tantin, Catherine Lombard-Bohas, Thomas Walter
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
Hyun Sun Woo, Hee Kyung Ahn, Ha Yeon Lee, Inkeun Park, Young Saing Kim, Junshik Hong, Sun Jin Sym, Jinny Park, Jae Hoon Lee, Dong Bok Shin, Eun Kyung Cho
Contributions from emerging transcriptomics technologies and computational strategies for drug discovery
Onat Kadioglu, Thomas Efferth